- $41.45m
- $29.09m
- $1.12m
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout
Brief: Renovorx Announces $10 Million At Market Private Placement
Brief: Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives
Brief: RenovoRx May Offer Securities For Up To $50 Million - SEC Filing
Cancer drug developer RenovoRx's Q3 net loss widens
Brief: RenovoRx Q3 Net Income USD -2.912 Million
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: RenovoRx Q2 Net Income USD -2.895 Million
RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: RenovoRx Q1 Net Income USD -2.4 Million
RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx’S Ongoing Phase III Tiger-Pac Clinical Trial
Brief: Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community